TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against DexCom, Inc. for securities fraud. The complaint alleges that DexCom made unauthorized changes to its G6 and G7 glucose monitoring systems without FDA approval, resulting in reduced reliability and health risks to users. The company allegedly downplayed the severity of these risks in public statements during the class period from July 26, 2024 to September 17, 2025.

Insights
RJF   neutral

Mentioned as a conference host with no specific positive or negative context


DXCM   negative

The company is accused of making false and misleading statements, making unauthorized product changes without FDA approval, reducing product reliability, and downplaying health risks to consumers. These allegations of fraud and regulatory violations represent significant legal and reputational risks.